Ticker: EAGB

Emerge goes live with Cathie Wood, CEO/CIO, ARK Invest on January 20th at 330pm ET

Investment Objectives

EAGB is an actively managed exchange-traded fund (ETF) that seeks to achieve long-term growth of capital by investing primarily, under normal circumstances, in the global equity securities of companies that are, or are expected to be, focused on extending and enhancing the quality of human and other life through technological and scientific developments, improvements and advancements in genomics

Profile of an Innovator : Portfolio Manager

Catherine Wood founded ARK Investment Management in 2014. She spent the previous 12 years at Alliance Bernstein as Chief Investment Officer of Global Thematic Strategies that had over US$5 billion in assets under management. Before AllianceBernstein, she worked for 18 years with Jennison Associates as Chief Economist, Equity Research Analyst, Portfolio Manager and Director. Catherine started her career in Los Angeles at the Capital Group as an Assistant Economist.

Why Invest?

Exposure to Innovation: Aims to achieve thematic multi-capitalization exposure to innovation across sectors. ARK believes the securities held in EARK present the best risk-reward opportunities from ARK’s innovation-based themes.

Growth Potential: Aims to capture long-term growth with low correlation of relative returns to traditional growth strategies and negative correlation to value strategies.

Tool for Diversification: Active stock selection results in little overlap with traditional indices. EAGB can be a complement to traditional value/growth strategies.

Grounded in Research: Combines top-down and bottom-up research in its portfolio management to identify innovative companies and convergence across markets.

Cost Effective: Provides a lower-cost alternative to mutual funds with true active management in an ETF that invests in rapidly moving themes.

Top 10 Holdings

As at December 31, 2020

Pacific Biosciences of California Inc 6.87%
Teladoc Health Inc5.96%
Twist Bioscience Corporation5.75%
CRISPR Therapeutics AG5.49%
CareDx Inc3.89%
Iovance Biotherapeutics Inc3.65%
EXACT Sciences Corporation3.63%
Fate Therapeutics Inc3.53%
Invitae Corporation3.49%
Personalis Inc.3.28%
Click Here to Download EAGB Full Holdings Report as of Nov. 30, 2020.
Fund Facts

EAGB NAV (As at January 14th, 2021):
EAGB.U NAV (As at January 14th, 2021):

CUSIP CAD Series: 291004109
CUSIP USD Series: 291004208
EXCHANGE: NEO Stock Exchange
SUB-ADVISORS: ARK Investment Management LLC

Fund Characteristics

As at December 31, 2020

  • Americas 82.01%
  • Europe 13.69%
  • Middle East 1.61%
  • Asia 2.11%
Sector Allocation

As at December 31, 2020

  • Health Care 94.33%
  • Information Technology 2.61%
  • Communication Services 2.07%
  • Financials 0.41%